Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free survival (PFS) benefit versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated intermediate- or high-risk diffuse large B-cell lymphoma (DLBCL; median follow-up: 28 months). In this 5-year update, sustained PFS benefits favoring Pola-R-CHP were observed. In the global intention-to-treat population (N = 879; median follow-up: 64.1 months), Pola-R-CHP demonstrated a significant PFS benefit over R-CHOP (hazard ratio [HR], 0.77 [95% CI, 0.62 to 0.97]), with 5-year PFS rates of 64.9% (95% CI, 59.8 to 70.0) and 59.1% (95% CI, 53.9 to 64.3), respectively. Although not statistically significant, overall survival analysis showed a HR of 0.85 (95% CI, 0.63 to 1.15) at the 5-year data cut compared with 0.94 (95% CI, 0.67 to 1.33) at the 2-year data cut. In the expanded population, 46 and 62 patients had lymphoma-related deaths in the Pola-R-CHP and R-CHOP arms, respectively. Exploratory analyses showed favorable 5-year survival rates with Pola-R-CHP in high-risk subgroups, including activated B-cell DLBCL and International Prognostic Index score 3-5. Long-term tolerability was similar between treatment arms. Findings confirm Pola-R-CHP represents a standard of care for frontline treatment of DLBCL.
Authors
- Hervé Tilly (ORCID: https://orcid.org/0000-0001-7022-5246)
- Shinya Rai (ORCID: https://orcid.org/0000-0003-3929-9751)
- Matthew Sugidono (ORCID: https://orcid.org/0000-0003-4883-8921)
- Pau Abrisqueta (ORCID: https://orcid.org/0000-0001-9625-7422)
- Lucie Obéric (ORCID: https://orcid.org/0000-0002-0039-1983)
- Jeff P. Sharman (ORCID: https://orcid.org/0000-0001-5611-6115)
- Yanwen Jiang (ORCID: https://orcid.org/0000-0002-9894-6560)
- Matthew C. Cheung (ORCID: https://orcid.org/0000-0003-3193-5872)
- Laurie H. Sehn (ORCID: https://orcid.org/0000-0003-1860-9765)
- Koji Izutsu (ORCID: https://orcid.org/0000-0001-9129-8057)
- Adrien Chauchet (ORCID: https://orcid.org/0000-0003-3665-6805)
- Jyh-Pyng Gau (ORCID: https://orcid.org/0000-0001-8670-5076)
- Alex Francisco Herrera (ORCID: https://orcid.org/0000-0002-9665-7415)
- Antonio Pinto (ORCID: https://orcid.org/0000-0002-9425-9026)
- Jonathan W. Friedberg (ORCID: https://orcid.org/0000-0002-1420-5563)
- Georg Lenz (ORCID: https://orcid.org/0000-0002-4728-1693)
- Richard Greil (ORCID: https://orcid.org/0000-0002-4462-3694)
- Charles Herbaux (ORCID: https://orcid.org/0000-0003-4910-476X)
- Connie Lee Batlevi (ORCID: https://orcid.org/0000-0002-9036-9463)
- Matthew J. Matasar (ORCID: https://orcid.org/0000-0002-4581-3721)
- Franck Morschhauser (ORCID: https://orcid.org/0000-0002-3714-9824)
- John M. Burke (ORCID: https://orcid.org/0000-0002-5144-6710)
- Neha Mehta–Shah (ORCID: https://orcid.org/0000-0001-5744-0670)
- Juan Bergua (ORCID: https://orcid.org/0000-0001-8229-1208)
- Greg Hapgood (ORCID: https://orcid.org/0000-0002-7980-8496)
- Christopher R. Flowers (ORCID: https://orcid.org/0000-0002-9524-3990)
- Saibah Chohan
- Gilles Salles (ORCID: https://orcid.org/0000-0002-9541-8666)
- Marek Trněný (ORCID: https://orcid.org/0000-0002-6952-6073)
- Larysa Mykhalska
- Ho‐Jin Shin (ORCID: https://orcid.org/0009-0009-5835-9028)
- Wojciech J. Jurczak (ORCID: https://orcid.org/0000-0003-1879-8084)
- Graham P. Collins (ORCID: https://orcid.org/0000-0002-8803-4234)
- Bruce McCall
- Mark Yan
- Yuqin Song
- Eduardo Munhoz
Institutions
- Rutgers, The State University of New Jersey (US)
- Hebron University (PS)
- Sunnybrook Health Science Centre (CA)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of British Columbia (CA)
- The University of Queensland (AU)
- Université de Montpellier (FR)
- Peking University (CN)
- Washington University in St. Louis (US)
- Charles University (CZ)
- Université de Lille (FR)
- Paracelsus Medical University (AT)
- Princess Alexandra Hospital (AU)
- Spinal Cord Injury BC (CA)
- Health Sciences Centre (CA)
- Taipei Veterans General Hospital (TW)
- Centre Hospitalier Universitaire de Besançon (FR)
- Roche (Canada) (CA)
- Peking University Cancer Hospital (CN)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- University Hospital Münster (DE)
- Hospital Erasto Gaertner (BR)
- City of Hope (US)
- Hospital San Pedro de Alcántara (ES)
- Pusan National University Hospital (KR)
- Vall d'Hebron Hospital Universitari (ES)
- Rocky Mountain Cancer Centers (US)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Oxford University Hospitals NHS Trust (GB)
- Kyiv City Clinical Oncology Center (UA)
- Willamette Valley Cancer Institute and Research Center (US)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Tokyo National Hospital (JP)
- University of Rochester (US)
- Université de Rouen Normandie (FR)
- Kindai University (JP)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1200/jco-25-00925
- Citations
- 12
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 19.50